Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Oncology·MeSH: Immunoblastic Lymphadenopathy
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)?
There are 1 clinical trial targeting Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) tracked by BioSniper.
What is the prevalence of Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)?
The estimated prevalence of Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) is approximately 56.0 per 100,000 population.
Deep-dive into Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis